Automate Your Wheel Strategy on ERAS
With Tiblio's Option Bot, you can configure your own wheel strategy including ERAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ERAS
- Rev/Share 0.0
- Book/Share 0.141
- PB 10.281
- Debt/Equity 0.1272
- CurrentRatio 12.352
- ROIC -0.3394
- MktCap 410766150.0
- FreeCF/Share -0.0381
- PFCF -3.8097
- PE -26.0615
- Debt/Assets 0.1078
- DivYield 0
- ROE -0.3656
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ERAS | Raymond James | -- | Outperform | -- | $5 | March 26, 2025 |
News
Erasca, Inc.: Carving A Different Niche In RAS Signaling
ERAS
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk.
Read More
About Erasca, Inc. (ERAS)
- IPO Date 2021-07-16
- Website https://www.erasca.com
- Industry Biotechnology
- CEO Jonathan E. Lim
- Employees 103
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.